Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights
November 15, 2021
Ryan Allway November 15th, 2021 Psychedelics FDA Authorization of Historic Phase I Clinical Trial Using All-Natural Psychedelic Compounds andDirect Psilocin Administration for the First Time Granted First and Only Patent for Extraction and Standardization of Natural Psilocybin Health Canada Dealer’s License Enables Production and Distribution of All Natural cGMP-GradePsychedelic... Read more
Silo Pharma Reports Third Quarter Results and Operating Highlights
November 11, 2021
Ryan Allway November 11th, 2021 Psychedelics, Top News Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update... Read more
Ryan Allway November 10th, 2021 Psychedelics Toronto, Ontario–(Newsfile Corp. – November 10, 2021) – Nutritional High International Inc. (CSE: EAT) (“Nutritional High” or the “Company“) is pleased to announce the name change of its wholly-owned subsidiary Psychedelic Science Corp., which it acquired in August 2020 (please see the press... Read more
Ryan Allway November 5th, 2021 Psychedelics, Top News Wonderland: Miami is hosted by Microdose and engages some of the greatest minds in the Psychedelic Sector, by fostering creative and professional growth Miami, Florida–(Newsfile Corp. – November 5, 2021) – Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of... Read more
Silo Pharma’s Sponsored Research Agreement with Columbia Could Yield a New Alzheimer’s Disease Treatment
November 3, 2021
Ryan Allway November 3rd, 2021 Psychedelics, Top Story Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet,... Read more
Ryan Allway November 1st, 2021 Psychedelics These data have given atai confidence to support an accelerated clinical development timeline NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”) today announced that it has observed encouraging interim data from the first 8-patient cohort of its... Read more
BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies
October 29, 2021
Ryan Allway October 29th, 2021 Psychedelics VANCOUVER, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to... Read more
How eHave is Quietly Building a Leading EHR Platform
October 27, 2021
Ryan Allway October 27th, 2021 Psychedelics, Top News The medical software industry is ripe for innovation. Unfortunately, many providers still use paper forms or outdated EHR platforms to manage patient billing and health records. The good news is that newer EHR platforms are popping up to address critical shortcomings,... Read more
Delic Announces Partnership with GT Research
October 26, 2021
Ryan Allway October 26th, 2021 Co-Marketing Agreement to Offer Computational Genetic Analysis and Trait Optimization for Cannabis and Psychedelics VANCOUVER, BC, Oct. 26, 2021 /CNW/ – Delic Holding Corp Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world,... Read more
Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
October 26, 2021
Ryan Allway October 26th, 2021 Psychedelics Output will be used to advance clinical testing of MEAI as a treatment for Alcohol Use Disorder and Binge Drinking TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech... Read more
